Results 261 to 270 of about 141,437 (356)

Characterization of Circulating Maternal Progestagens, Estrogens, Androgens and Glucocorticoids During Normal Pregnancy in Belugas (<i>Delphinapterus leucas</i>) Under Human Care. [PDF]

Animals (Basel)
Steinman KJ, Montano GA, Robeck TR.
europepmc   +1 more source

Androgen Synthesis Inhibitors vs Androgen Receptor Inhibitors and Survival in Metastatic Hormone-Sensitive Prostate Cancer

Georges Gebrael, Yeonjung Jo, Varun Nandakumar, Zeynep İrem Özay, Chiara Mercinelli, Gabriel A. Hooper, Micah Ostrowski, Nicolas Sayegh, Edwin Lin, Krishnam Goel, Haoran Li, Vinay Mathew Thomas, Sumati Gupta, Avirup Guha, Irbaz Bin Riaz, Neeraj Agarwal, Umang Swami   +16 more
openalex   +1 more source

Insulin‐Like Growth Factor Axis and Survival in Metastatic Hormone‐Sensitive Prostate Cancer: Post‐Hoc Analysis From the ENZAMET Phase 3 Trial

The Prostate, EarlyView.
ABSTRACT Background A higher ratio of IGF‐1:IGF binding protein 1 (IGFBP1) was associated with improved prognosis in the CHAARTED trial of docetaxel in participants with metastatic hormone‐sensitive prostate cancer (mHSPC). The ENZAMET trial demonstrated the survival benefit of adding enzalutamide to androgen deprivation therapy (ADT) in mHSPC, and ...
Michael A. Cilento, Hui‐Ming Lin, Nicole Yeung, Rachel M.N. Kim, Neil Portman, Martin R. Stockler, Andrew J. Martin, Vinod Subhash, Sonia Yip, Lisa M. Butler, Ian C. Marschner, Peter J. Meikle, Arun A. Azad, Ian D. Davis, Lisa G. Horvath, Christopher J. Sweeney   +15 more
wiley   +1 more source

Anti-androgen therapy in polyendocrine metabolic ovary syndrome (PMOS, formerly PCOS): efficacy, safety, and phenotype-oriented clinical decision-making. [PDF]

J Ovarian Res
Peng H, Jiang J, Wang Z, Wang W.
europepmc   +1 more source

Survival Outcomes by Frailty and Comorbidities in Veterans Treated With Abiraterone and Enzalutamide for Metastatic Castration‐Resistant Prostate Cancer

The Prostate, EarlyView.
ABSTRACT Background Androgen receptor pathway inhibitors (ARPIs) such as abiraterone and enzalutamide are common therapies in the management of metastatic castration‐resistant prostate cancer (mCRPC). However, the comparative effectiveness of these oral ARPIs in frail and comorbid patient populations remains uncertain.
Meghana Yellanki, Jennifer La, Danne C. Elbers, Nhan V. Do, Channing J. Paller, Nathanael R. Fillmore, Martin W. Schoen   +6 more
wiley   +1 more source

Human Prostate Cell Lines: Derivation, Molecular Characteristics and Appropriate Use

The Prostate, EarlyView.
ABSTRACT Background Research on prostate cancer and benign prostatic hyperplasia depends on a small number of immortalized human cell lines established between 1977 and 2001, most of them from advanced metastatic disease. The cell lines differ from one another in androgen receptor status, prostate‐specific antigen secretion, p53 status, karyotype and ...
Hamza Abohamra, Keenau Mark Pearce
wiley   +1 more source

Prognostic Value of MRI‐Derived Apparent Diffusion Coefficient in Intermediate‐Risk Prostate Cancer Treated With Definitive Radiotherapy

The Prostate, EarlyView.
ABSTRACT Background Intermediate‐risk prostate cancer (IR‐PCa) is a heterogeneous disease with variable clinical outcomes despite established risk classification. We evaluated whether pretreatment tumor apparent diffusion coefficient (ADC) derived from multiparametric MRI was associated with long‐term outcomes and provided additional prognostic ...
Cem Onal, Gurcan Erbay, Aysenur Elmali, Birhan Demirhan, Ozan Cem Guler   +4 more
wiley   +1 more source

Multi-Cycle Dosimetry of the Albumin-Binding Prostate-Specific Membrane Antigen Ligand [177Lu]Ludotadipep in Metastatic Androgen Pathway Modulator-Resistant Prostate Cancer with Adjusted Red Marrow Modeling

Seunggyun Ha, Joo Hyun O, Chansoo Park, Sun Ha Boo, Dong‐Ho Shin, Hyong Woo Moon, Ie Ryung Yoo, In-Ho Kim, Ji Youl Lee   +8 more
openalex   +1 more source

Evaluation of Time to Metastasis After Prostatectomy as a Prognostic Factor in Patients With Metachronous mHSPC: A Secondary Analysis of the SWOG‐1216 Phase 3 Trial

The Prostate, EarlyView.
ABSTRACT Background The prognostic significance of time to metastasis (TTM) following radical prostatectomy in patients with metachronous metastatic hormone‐sensitive prostate cancer (mHSPC) remains uncertain. We performed a secondary analysis of patient‐level data from the phase 3 SWOG 1216 randomized clinical trial to evaluate whether TTM is ...
Nicolas Sayegh, Yeonjung Jo, Umang Swami, Varun Nandakumar, Georges Gebrael, Zeynep Irem Ozay, Haoran Li, Krishnam Goel, Benjamin L. Maughan, Melissa Plets, Maha H. A. Hussain, Tanya B. Dorff, Primo N. Lara Jr., Amir Goldkorn, Seth P. Lerner, Neeraj Agarwal   +15 more
wiley   +1 more source